Actively Recruiting
First-In-Human Study of EG110A Injections for Adults With Neurogenic Detrusor Overactivity-Related Incontinence After Spinal Cord Injury Who Use Clean Intermittent Catheterization
Led by Cyllene Therapeutics · Updated on 2026-09-03
16
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating EG110A, a new drug given by injections into the bladder muscle, in adults with Neurogenic Detrusor Overactivity NDO-related urinary incontinence following spinal cord injury. The study focuses on participants who have persistent incontinence despite standard treatments and regularly perform clean intermittent catheterization. This first-in-human, open-label Phase 1b2a trial aims to assess the safety, tolerability, and initial effectiveness of EG110A in this population. Participants receive a single treatment course consisting of multiple intradetrusor injections of EG110A at varying dose levels low, middle, and low-low doses. The trial explores dose escalation to find suitable doses for future studies. Patients are grouped based on the dose they receive, and the study collects data through bladder diaries and urodynamic assessments to evaluate treatment impact. During the study, participants are monitored for adverse events over one year. They complete bladder diaries and undergo urodynamic testing at baseline, Week 12, and Week 52 to measure changes in urinary episodes and bladder function. The study lasts up to one year, focusing on safety and efficacy outcomes, with ongoing assessments of symptoms and treatment effects throughout the period.
CONDITIONS
Brief Title
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
Research Team
S
Sandrine Zourbas, Ph.D.
C
Cornelia Haag-Molkenteller, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here